Form 4: United Therapeutics Director Exercises, Sells Shares

United Therapeutics Director Christopher Patusky exercised stock options and sold 1,000 shares of common stock in a pre-planned transaction.

Summary

• Christopher Patusky, a Director at United Therapeutics Corp (UTHR), engaged in an insider transaction on December 15, 2025.
• Patusky exercised 1,000 stock options at an exercise price of $101.8 per share.
• Concurrently, Patusky sold 1,000 shares of common stock at a weighted average price of $495.9539 per share.
• The sale was executed in multiple trades ranging from $495.64 to $496.09.
• Following these transactions, Patusky directly owns 1,490 shares of common stock and indirectly owns 1,100 shares through a Trust.
• Patusky also holds 3,910 derivative securities (stock options) directly after the exercise.
• The transaction was made pursuant to a Rule 10b5-1(c) contract, instruction, or written plan.

Sentiment

Score: 5

Explanation: The transaction represents a routine exercise of options and subsequent sale of shares, often for liquidity or tax purposes, especially given it was pre-planned under a 10b5-1 plan. While it reduces direct insider ownership, it does not necessarily signal a change in confidence in the company's future prospects.

Positives

• The exercise of stock options indicates the director realized value from their compensation, with a significant difference between the exercise price ($101.8) and the sale price ($495.9539).
• The transaction was conducted under a Rule 10b5-1(c) plan, suggesting it was pre-planned and not based on immediate, non-public information.

Negatives

• The direct beneficial ownership of common stock by Director Christopher Patusky decreased by 1,000 shares following the sale.

Future Outlook

NA

Industry Context

NA

Stakeholder Impact

• Shareholders may note the reduction in direct insider ownership, which can sometimes be interpreted as a neutral to slightly negative signal, though the pre-planned nature mitigates this.

Key Dates

Recommendation

This Form 4 filing details a pre-planned insider transaction involving the exercise of stock options and the subsequent sale of shares. Such transactions are common for liquidity or tax planning and, especially when conducted under a Rule 10b5-1 plan, are not typically strong indicators of future company performance or a change in management's outlook. While direct insider ownership decreased, this single event does not provide sufficient new information to warrant a change from a 'hold' recommendation.

Keywords

UTHR, United Therapeutics, insider transaction, Form 4, stock options, share sale, director, 10b5-1 plan